Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee

Although children with rare cancers enrolled in COG studies reflect the US population, enrollment in the COG registry/biospecimen repository continues to be limited in the absence of therapeutic trials, impacting data and biospecimens available to inform therapeutic trial development. Expansion of therapeutic trials or free molecular testing through the Molecular Characterization Initiative may increase data and biospecimens for these rare cancers.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2025-12-26
DOI
https://doi.org/10.1002/pbc.32164
Primary Topic
Childhood Cancer Survivors' Quality of Life
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee

Junne Kamihara, Jin Piao, T. Laetsch, Sarah G. Mitchell et al.
Pediatric Blood & Cancer
Childhood Cancer Survivors' Quality of Life
article

Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee

Junne Kamihara, Jin Piao, T. Laetsch, Sarah G. Mitchell, Samara L. Poplack Potter, Kenneth Chen, Hetal Dholaria, Michael R. Sargen, Jennifer H. Aldrink, Farzana Pashankar, Mary Frances Frances Wedekind, Robyn Gartrell, Jeremy Rosenblum, Brian R. Englum, M. John Hicks, Emily Christison‐Lagay, Kris Ann P. Schultz, Lindsay Younis, Brittani K. N. Seynnaeve, Manuela Orjuela‐Grimm, Reto M. Baertschiger
article en

Abstract

Although children with rare cancers enrolled in COG studies reflect the US population, enrollment in the COG registry/biospecimen repository continues to be limited in the absence of therapeutic trials, impacting data and biospecimens available to inform therapeutic trial development. Expansion of therapeutic trials or free molecular testing through the Molecular Characterization Initiative may increase data and biospecimens for these rare cancers.

Pediatric Blood & CancerVol. 73(2)
Children's Oncology Group (CH), University of Maryland, Baltimore (US), Nationwide Children's Hospital (US), Children's Hospital of Philadelphia (US), Johns Hopkins University (US), University of Pittsburgh (US), The Kids Research Institute Australia (AU), New York Medical College (US), Baylor College of Medicine (US), Columbia University Irving Medical Center (US), Johns Hopkins Medicine (US), Princess Margaret Hospital for Children (AU), Yale University (US), Children's Minnesota (US), Children's Oncology Group (US), National Cancer Institute (US), Children's Hospital at Dartmouth Hitchcock (US), Children's Healthcare of Atlanta (US), Texas Children's Hospital (US), Department of Health and Human Services (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), The Ohio State University (US), The University of Texas Southwestern Medical Center (US)
National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
Openalex Percentile: Top 18%
Childhood Cancer Survivors' Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.